Characterisation of the antibody response to a totally synthetic immunocontraceptive peptide vaccine based on LHRH. (Q46512462)

22 December 2017

title

Characterisation of the antibody response to a totally synthetic immunocontraceptive peptide vaccine based on LHRH. (English)

1 reference

22 December 2017

author

David Jackson

5

1 reference

22 December 2017

author name string

Weiguang Zeng

1

1 reference

22 December 2017

Sonja Gauci

2

1 reference

22 December 2017

Souravi Ghosh

3

1 reference

22 December 2017

John Walker

4

1 reference

22 December 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

22 December 2017

published in

Vaccine

1 reference

22 December 2017

volume

23

1 reference

22 December 2017

issue

35

1 reference

22 December 2017

page(s)

4427-4435

1 reference

22 December 2017

The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Preparation and properties of totally synthetic immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Lipopeptide vaccines--yesterday, today, and tomorrow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Promiscuous and allele-specific anchors in HLA-DR-binding peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Solid phase peptide synthesis of lipopeptide vaccines eliciting epitope‐specific B‐, T‐helper and T‐killer cell response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Optimisation of the immune response to foot-and-mouth disease vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Longevity of antibody and cytokine responses following vaccination with high potency emergency FMD vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

The measurement of relative antibody affinity by ELISA using thiocyanate elution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Long-lived plasma cells: a mechanism for maintaining persistent antibody production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Lifetime of plasma cells in the bone marrow.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

The relationship between the 140S antigen dose in aqueous foot-and-mouth disease vaccines and the serum antibody response of cattle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Local immune responses to influenza antigen are synergistically enhanced by the adjuvant ISCOMATRIX

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Induction of lymphocyte recruitment in the absence of a detectable immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Reduction of disulfide bonds during antigen processing: evidence from a thiol-dependent insulin determinant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Antigen unfolding and disulfide reduction in antigen presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.015

10.1016/J.VACCINE.2005.04.015

7 January 2021

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017